{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:50:42Z","timestamp":1791424242556,"version":"4.3.3"},"reference-count":115,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,7]],"date-time":"2027-10-07T00:00:00Z","timestamp":1822867200000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["AI-183533"],"award-info":[{"award-number":["AI-183533"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.pt.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:11:37Z","timestamp":1789657897000},"page":"1004-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["No single magic bullet: the case for combined interventions for global malaria elimination and eradication"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-4924","authenticated-orcid":false,"given":"Nirbhay","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2026.08.001_bb0005","series-title":"World Malaria Report","author":"WHO","year":"2025"},{"key":"10.1016\/j.pt.2026.08.001_bb0010","series-title":"Global Technical Strategy for Malaria","author":"WHO","year":"2015"},{"key":"10.1016\/j.pt.2026.08.001_bb0015","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12936-023-04796-9","article-title":"Assessing the histidine-rich protein 2\/3 gene deletion in Plasmodium falciparum isolates from Burkina Faso","volume":"22","author":"Tarama","year":"2023","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2026.08.001_bb0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2026.08.001_bb0025","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1016\/S1473-3099(24)00141-5","article-title":"The emergence of artemisinin partial resistance in Africa: how do we respond?","volume":"24","author":"Rosenthal","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2026.08.001_bb0030","series-title":"Handbook for Integrated Vector Management","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.pt.2026.08.001_bb0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12936-025-05339-0","article-title":"Enhancing malaria elimination in high-transmission settings: the synergy of concurrent vector control and chemotherapy","volume":"24","author":"Mulebeke","year":"2025","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2026.08.001_bb0040","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1080\/00034983.1997.11813239","article-title":"The problem of multiplicity in malaria vaccine development","volume":"91","author":"Mons","year":"1997","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/j.pt.2026.08.001_bb0045","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(23)01249-7","article-title":"Malaria","volume":"402","author":"Poespoprodjo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.001_bb0050","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0140-6736(19)31096-7","article-title":"Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000\u201317: a spatial and temporal modelling study","volume":"394","author":"Battle","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.001_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007140","article-title":"Growing evidence of Plasmodium vivax across malaria-endemic Africa","volume":"13","author":"Twohig","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2026.08.001_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpddr.2025.100602","article-title":"Antimalarial drug resistance and drug discovery: learning from the past to innovate the future","volume":"28","author":"Theodoridis","year":"2025","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2026.08.001_bb0065","series-title":"Multiple First-Line Therapies as Part of the Response to Antimalarial Drug Resistance: An Implementation Guide","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.pt.2026.08.001_bb0070","series-title":"Strategy to Respond to Antimalarial Drug Resistance in Africa","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.pt.2026.08.001_bb0075","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJMp1108322","article-title":"The threat of artemisinin-resistant malaria","volume":"365","author":"Dondorp","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2026.08.001_bb0080","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41579-024-01008-2","article-title":"Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa","volume":"22","author":"Rosenthal","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.pt.2026.08.001_bb0085","first-page":"739","article-title":"Antimalarial drug resistance and combination chemotherapy","volume":"354","author":"White","year":"1999","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.pt.2026.08.001_bb0090","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm.4381","article-title":"Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic","volume":"23","author":"Blasco","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.pt.2026.08.001_bb0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12936-021-03649-7","article-title":"Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations","volume":"20","author":"Tindana","year":"2021","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2026.08.001_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12936-024-04844-y","article-title":"Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts","volume":"23","author":"Kokori","year":"2024","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2026.08.001_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2024.11.006","article-title":"Triple artemisinin-based combination therapy (TACT): efficacy of dihydroartemisinin-piperaquine plus chloroquine against Plasmodium berghei ANKA strains with different drug sensitivities in a murine malaria model","volume":"31","author":"Akinola","year":"2025","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.pt.2026.08.001_bb0110","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","article-title":"Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial","volume":"395","author":"van der Pluijm","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.001_bb0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pt.2020.09.011","article-title":"Triple artemisinin-based combination therapies for malaria\u2014a new paradigm?","volume":"37","author":"van der Pluijm","year":"2021","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2026.08.001_bb0120","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1038\/s41467-023-39914-3","article-title":"Preventing antimalarial drug resistance with triple artemisinin-based combination therapies","volume":"14","author":"Nguyen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2026.08.001_bb0125","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1093\/jac\/dkab181","article-title":"Seeking an optimal dosing regimen for OZ439\/DSM265 combination therapy for treating uncomplicated falciparum malaria","volume":"76","author":"Dini","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2026.08.001_bb0130","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01068-18","article-title":"Investigating the efficacy of triple artemisinin-based combination therapies for treating Plasmodium falciparum malaria patients using mathematical modeling","volume":"62","author":"Dini","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2026.08.001_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003727","article-title":"Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: case\u2013control studies in 5 countries","volume":"18","author":"Cairns","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2026.08.001_bb0140","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/infdis\/jiaa498","article-title":"Efficacy of single-dose primaquine with artemisinin combination therapy on Plasmodium falciparum gametocytes and transmission: an individual patient meta-analysis","volume":"225","author":"Stepniewska","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2026.08.001_bb0145","doi-asserted-by":"crossref","DOI":"10.1080\/16549716.2023.2231257","article-title":"A comprehensive approach to optimizing malaria prevention in pregnant women: evaluating the efficacy, cost-effectiveness, and resistance of IPTp-SP and IPTp-DP","volume":"16","author":"Eisenberg","year":"2023","journal-title":"Glob. Health Action"},{"key":"10.1016\/j.pt.2026.08.001_bb0150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1471-0528.2010.02810.x","article-title":"Parasitological efficacy of antimalarials in the treatment and prevention of falciparum malaria in pregnancy 1998 to 2009: a systematic review","volume":"118","author":"McGready","year":"2011","journal-title":"BJOG"},{"key":"10.1016\/j.pt.2026.08.001_bb0155","first-page":"e157","article-title":"Beyond malaria: can intermittent preventive treatment with sulphadoxine-pyrimethamine reduce the number of small vulnerable newborns globally? Lancet Glob","volume":"14","author":"Unger","year":"2026","journal-title":"Health"},{"key":"10.1016\/j.pt.2026.08.001_bb0160","article-title":"Mass drug administration for malaria","volume":"2013","author":"Poirot","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pt.2026.08.001_bb0165","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.51773","article-title":"Determinants of MDA impact and designing MDAs towards malaria elimination","volume":"9","author":"Gao","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.pt.2026.08.001_bb0170","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41579-024-01065-7","article-title":"Malaria vaccines: a new era of prevention and control","volume":"22","author":"Duffy","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.pt.2026.08.001_bb0175","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40259-023-00623-4","article-title":"Malaria vaccines: progress to date","volume":"37","author":"Stanisic","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.pt.2026.08.001_bb0180","article-title":"Gradual acquisition of immunity to severe malaria with increasing exposure","volume":"282","author":"Griffin","year":"2015","journal-title":"Proc. R. Soc. B Biol. Sci."},{"key":"10.1016\/j.pt.2026.08.001_bb0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41182-023-00516-w","article-title":"Malaria vaccines: the 60-year journey of hope and final success\u2014lessons learned and future prospects","volume":"51","author":"El-Moamly","year":"2023","journal-title":"Trop. Med. Health"},{"key":"10.1016\/j.pt.2026.08.001_bb0190","article-title":"WHO hails \u201chistoric day\u201d as it recommends malaria vaccine","volume":"375","author":"Wise","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.pt.2026.08.001_bb0195","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/S0140-6736(21)01065-5","article-title":"R21\/Matrix-M: a second malaria vaccine?","volume":"397","author":"Moorthy","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.001_bb0200","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.001_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003377","article-title":"Estimated impact of RTS, S\/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: a modelling study","volume":"17","author":"Hogan","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2026.08.001_bb0210","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"Datoo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.001_bb0215","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1038\/s41467-022-30133-w","article-title":"Malaria in 2022: increasing challenges, cautious optimism","volume":"13","author":"Jagannathan","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2026.08.001_bb0220","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s12936-021-03998-3","article-title":"Supporting countries to achieve their malaria elimination goals: the WHO E-2020 initiative","volume":"20","author":"Lindblade","year":"2021","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2026.08.001_bb0225","series-title":"Update on the E-2020 Initiative of 21 Malaria-Eliminating Countries: Report and Country Briefs","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.pt.2026.08.001_bb0230","series-title":"Zeroing in on Malaria Elimination: Final Report of the E-2020 Initiative","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.pt.2026.08.001_bb0235","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41541-017-0015-7","article-title":"A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection","volume":"2","author":"Srinivasan","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.pt.2026.08.001_bb0240","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96381","article-title":"Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions","volume":"2","author":"Payne","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.pt.2026.08.001_bb0245","article-title":"First Phase 1b, single-center, age de-escalation trial of the P. falciparum blood-stage malaria vaccine candidate RH5.1\/Matrix-M\u2122: a delayed boost regimen induces high levels of functional antibodies in 5\u201317 month old Tanzanian infants","author":"Silk","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.pt.2026.08.001_bb0250","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1038\/s41467-023-40878-7","article-title":"Structure-based design of a strain transcending AMA1-RON2L malaria vaccine","volume":"14","author":"Patel","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2026.08.001_bb0255","article-title":"Protective immunity to clinical malaria is modified by the genetic diversity of P. falciparum antigens","author":"Naung","year":"2026","journal-title":"medRxiv"},{"key":"10.1016\/j.pt.2026.08.001_bb0260","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/CMR.00051-10","article-title":"Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination","volume":"24","author":"Bousema","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.pt.2026.08.001_bb0265","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/14760584.2024.2369583","article-title":"Immune mechanisms targeting malaria transmission: opportunities for vaccine development","volume":"23","author":"Bansal","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.pt.2026.08.001_bb0270","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.apar.2015.04.001","article-title":"Chapter three - development of malaria transmission-blocking vaccines: from concept to product","volume":"89","author":"Wu","year":"2015","journal-title":"Adv. Parasitol."},{"key":"10.1016\/j.pt.2026.08.001_bb0275","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/14760584.2025.2517720","article-title":"Advances in transmission-blocking vaccines against Plasmodium falciparum and Plasmodium vivax","volume":"24","author":"Tachibana","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.pt.2026.08.001_bb0280","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.vaccine.2004.12.019","article-title":"Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria","volume":"23","author":"Malkin","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.pt.2026.08.001_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002636","article-title":"Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51","volume":"3","author":"Wu","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2026.08.001_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163144","article-title":"Safety and immunogenicity of Pfs25-EPA\/Alhydrogel\u00ae, a transmission blocking vaccine against Plasmodium falciparum: an open label study in malaria na\u00efve adults","volume":"11","author":"Talaat","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2026.08.001_bb0295","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146221","article-title":"Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice","volume":"131","author":"Healy","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.pt.2026.08.001_bb0300","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1473-3099(23)00276-1","article-title":"Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial","volume":"23","author":"Sagara","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2026.08.001_bb0305","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400188","article-title":"A vaccine to block Plasmodium falciparum transmission","volume":"4","author":"Healy","year":"2025","journal-title":"NEJM Evid."},{"key":"10.1016\/j.pt.2026.08.001_bb0310","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/infdis\/jiaf555","article-title":"Pfs230 domains 7\u201310 encoded by DNA vaccines induce potent complement-independent transmission-blocking antibody against Plasmodium falciparum","volume":"233","author":"Cao","year":"2025","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2026.08.001_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126696","article-title":"Distinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1","volume":"47","author":"Cao","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.pt.2026.08.001_bb0320","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.vaccine.2012.01.003","article-title":"Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate","volume":"30","author":"Tachibana","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.pt.2026.08.001_bb0325","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/156652321403140819122538","article-title":"Improving DNA vaccine performance through vector design","volume":"14","author":"Williams","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.pt.2026.08.001_bb0330","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.pt.2026.08.001_bb0335","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.pt.2026.08.001_bb0340","first-page":"111","article-title":"Messenger RNA-based vaccines against infectious diseases","volume":"440","author":"Alameh","year":"2020","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.pt.2026.08.001_bb0345","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pt.2026.08.001_bb0350","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/S0140-6736(26)01124-4","article-title":"Single-dose mRNA vaccines against Andes hantavirus","volume":"407","author":"Meyer","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.001_bb0355","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0140-6736(26)00512-X","article-title":"Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective","volume":"408","author":"Blakney","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.001_bb0360","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41541-022-00577-8","article-title":"mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum","volume":"7","author":"Hayashi","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.pt.2026.08.001_bb0365","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-021-00345-0","article-title":"Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice","volume":"6","author":"Mallory","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.pt.2026.08.001_bb0370","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41541-023-00786-9","article-title":"A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax","volume":"8","author":"Kunkeaw","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.pt.2026.08.001_bb0375","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41541-025-01296-6","article-title":"mRNA delivery of circumsporozoite protein epitope-based malaria vaccines induces protection in a mouse model","volume":"10","author":"Wu","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.pt.2026.08.001_bb0380","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41541-023-00783-y","article-title":"mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response","volume":"9","author":"Scaria","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.pt.2026.08.001_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102645","article-title":"mRNA-LNP vaccine encoding the Plasmodium vivax circumsporozoite protein is highly immunogenic and confers protection in mice","volume":"36","author":"Limsalakpetch","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.pt.2026.08.001_bb0390","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1473-3099(24)00752-7","article-title":"Safety and efficacy of the blood-stage malaria vaccine RH5.1\/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children","volume":"25","author":"Natama","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2026.08.001_bb0395","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41541-025-01262-2","article-title":"A combined designed CSP and Pfs48\/45 infection and transmission blocking vaccine for malaria","volume":"10","author":"Gupta","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.pt.2026.08.001_bb0400","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.1038\/s41467-024-51701-2","article-title":"Multistage protective anti-CelTOS monoclonal antibodies with cross-species sterile protection against malaria","volume":"15","author":"Tang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2026.08.001_bb0405","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1038\/s41467-024-50770-7","article-title":"A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites","volume":"15","author":"Angage","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2026.08.001_bb0410","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/bs.apar.2018.01.003","article-title":"Expanding the vector control toolbox for malaria elimination: a systematic review of the evidence","volume":"99","author":"Williams","year":"2018","journal-title":"Adv. Parasitol."},{"key":"10.1016\/j.pt.2026.08.001_bb0415","article-title":"Larviciding to prevent malaria transmission","volume":"8","author":"Choi","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pt.2026.08.001_bb0420","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-091569","article-title":"Integrated malaria vector control strategies and their effectiveness in sub-Saharan Africa: a systematic review protocol for interventional studies","volume":"15","author":"Kombate","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.pt.2026.08.001_bb0425","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1475-2875-7-S1-S4","article-title":"Integrated vector management for malaria control","volume":"7","author":"Beier","year":"2008","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2026.08.001_bb0430","article-title":"Indoor residual spraying for preventing malaria in communities using insecticide-treated nets","volume":"2022","author":"Pryce","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pt.2026.08.001_bb0435","article-title":"Indoor residual spraying for preventing malaria in communities using insecticide-treated nets","volume":"5","author":"Choi","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pt.2026.08.001_bb0440","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.pt.2026.03.013","article-title":"Metabolic insecticide resistance DNA markers in malaria vectors","volume":"42","author":"Tchouakui","year":"2026","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2026.08.001_bb0445","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(18)30427-6","volume":"391","author":"Protopopoff","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.001_bb0450","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad3270","article-title":"Efficacy of the Olyset Duo net against insecticide-resistant mosquito vectors of malaria","volume":"8","author":"Ngufor","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2026.08.001_bb0455","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12936-022-04041-9","article-title":"Comparative efficacy of two pyrethroid-piperonyl butoxide nets (Olyset Plus and PermaNet 3.0) against pyrethroid resistant malaria vectors: a non-inferiority assessment","volume":"21","author":"Ngufor","year":"2022","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2026.08.001_bb0460","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0140-6736(14)61007-2","article-title":"Efficacy of indoor residual spraying with dichlorodiphenyltrichloroethane against malaria in Gambian communities with high usage of long-lasting insecticidal mosquito nets: a cluster-randomised controlled trial","volume":"385","author":"Pinder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.001_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0005306","article-title":"Durability of the insecticidal activity of next-generation insecticide treated nets distributed for malaria control in Mozambique: findings from the new nets project (2020\u20132022)","volume":"6","author":"Fagbohoun","year":"2026","journal-title":"PLOS Glob. Public Health"},{"key":"10.1016\/j.pt.2026.08.001_bb0470","series-title":"Global Report on Insecticide Resistance in Malaria Vectors, WHO","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.pt.2026.08.001_bb0475","series-title":"Guidelines for Malaria Vector Control","author":"WHO","year":"2025"},{"key":"10.1016\/j.pt.2026.08.001_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(26)00066-5","article-title":"Adaptive intervention strategies for malaria vector control in western Kenya: a cluster, sequential, multiple-assignment, randomised, open-label trial","volume":"14","author":"Zhou","year":"2026","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.pt.2026.08.001_bb0485","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.pt.2015.11.010","article-title":"Insecticide resistance in African Anopheles mosquitoes: a worsening situation that needs urgent action to maintain malaria control","volume":"32","author":"Ranson","year":"2016","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2026.08.001_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006499","article-title":"Consequences of insecticide resistance on malaria transmission","volume":"13","author":"Alout","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2026.08.001_bb0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002588","article-title":"Ross, Macdonald, and a theory for the dynamics and control of mosquito-transmitted pathogens","volume":"8","author":"Smith","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2026.08.001_bb0500","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025460","article-title":"Malaria modeling in the era of eradication","volume":"7","author":"Smith","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.pt.2026.08.001_bb0505","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41591-022-01756-9","article-title":"Dynamical malaria modeling as a tool for bold policy-making","volume":"28","author":"Owen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.pt.2026.08.001_bb0510","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40249-022-00981-1","article-title":"Leveraging mathematical models of disease dynamics and machine learning to improve development of novel malaria interventions","volume":"11","author":"Golumbeanu","year":"2022","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.pt.2026.08.001_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002453","article-title":"malERA: an updated research agenda for combination interventions and modelling in malaria elimination and eradication","volume":"14","author":"malERA Refresh Consultative Panel on Combination Interventions and Modelling","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2026.08.001_bb0520","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.inhe.2010.09.005","article-title":"The role of mathematical modelling in guiding the science and economics of malaria elimination","volume":"2","author":"Maude","year":"2010","journal-title":"Int. Health"},{"key":"10.1016\/j.pt.2026.08.001_bb0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000324","article-title":"Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies","volume":"7","author":"Griffin","year":"2010","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2026.08.001_bb0530","doi-asserted-by":"crossref","first-page":"e1782","DOI":"10.1016\/S2214-109X(22)00416-8","article-title":"Seasonal use case for the RTS, S\/AS01 malaria vaccine: a mathematical modelling study","volume":"10","author":"Thompson","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.pt.2026.08.001_bb0535","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","article-title":"Public health impact and cost-effectiveness of the RTS, S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models","volume":"387","author":"Penny","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2026.08.001_bb0540","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1016\/S2214-109X(17)30220-6","article-title":"Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study","volume":"5","author":"Brady","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.pt.2026.08.001_bb0545","doi-asserted-by":"crossref","DOI":"10.1080\/27684830.2026.2648894","article-title":"A systematic review of mathematical models with optimal control strategies for malaria management from 2010 to 2024","volume":"13","author":"Chuma","year":"2026","journal-title":"Res. Math."},{"key":"10.1016\/j.pt.2026.08.001_bb0550","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41591-021-01492-6","article-title":"Malaria: a problem to be solved and a time to be bold","volume":"27","author":"Alonso","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.pt.2026.08.001_bb0555","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","article-title":"Seasonal malaria vaccination with or without seasonal malaria chemoprevention","volume":"385","author":"Chandramohan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2026.08.001_bb0560","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035433","article-title":"Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS, S\/AS01E vaccine, seasonal malaria chemoprevention and the combination of vaccination and chemoprevention","volume":"10","author":"Chandramohan","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.pt.2026.08.001_bb0565","series-title":"Guiding Principles for Prioritizing Malaria Interventions in Resource-Constrained Country Contexts to Achieve Maximum Impact","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.pt.2026.08.001_bb0570","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.pt.2026.03.010","article-title":"Adapting Africa\u2019s vector surveillance systems to monitor gene-drive mosquitoes in malaria control","volume":"42","author":"Okumu","year":"2026","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2026.08.001_bb0575","doi-asserted-by":"crossref","first-page":"8976","DOI":"10.1038\/s41467-024-53065-z","article-title":"The potential of gene drives in malaria vector species to control malaria in African environments","volume":"15","author":"Hancock","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492226002291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492226002291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:58:38Z","timestamp":1791421118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492226002291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":115,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1471492226002291"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2026.08.001","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No single magic bullet: the case for combined interventions for global malaria elimination and eradication","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}